Workflow
东诚药业(002675.SZ):控股子公司获得药物临床试验批准通知书

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary Yantai Lannacheng Biotechnology Co., Ltd. received approval from the National Medical Products Administration of China for the clinical trial of Ac-LNC1011 injection, which will soon commence clinical trials [1] Group 1 - The product Ac-LNC1011 injection is a targeted alpha-particle radiotherapy drug aimed at treating patients with advanced prostate cancer expressing Prostate Specific Membrane Antigen (PSMA) [1] - Alpha particles have a shorter range compared to traditional particles, which may enhance the treatment's effectiveness [1]